Therapix Biosciences has signed a licensing agreement with Yissum Research Development Company for nasal drug delivery technology that it plans to use for intranasal delivery of cannabinoids, the company said. Yissum Research Development Company is Hebrew University’s technology transfer company.
In 2016, Therapix announced that it had licensed an intranasal formulation of cannabinoids from Yissum. The new license, which is exclusive, global, and sub-licensable, covers technology developed by Hebrew University Professor Elka Touitou for improved nasal absorption of tetrahydrocannabinol.
Therapix CEO Elran Haber commented, “This agreement with Yissum paves the way for the development and marketing of new cannabinoid-based treatment offerings for people suffering from a variety of neurological conditions. Compared with standard oral administration, we expect the nasal delivery technology developed by Professor Touitou and her team at Hebrew University to offer improved bioavailability, efficacy, and a shorter reaction time for patients.”
Read the Therapix Biosciences press release.
